Asia Pacific Metastatic Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous and Intramuscular), Drug Class (HER2 Inhibitors, Immune Checkpoint Inhibitors, PARP Inhibitors, Kinase Inhibitors, and Others), Product (Branded, Generics, and Biosimilars), and End User (Hospital, Specialty Clinic, and Others)
The Asia Pacific metastatic cancer drugs market is expected to reach US$ 11,626.26 million by 2028 from US$ 7,985.76 million in 2021; it is estimated to grow at a CAGR of 5.5% from 2021 to 2028.
Advancements in artificial intelligence (AI) are anticipated to transform every industry. In drug discovery and development, time and costs required are key challenges to sustain the drug development pipeline. The development of oncology therapeutics is estimated to cost over US$ 2.6 billion to the manufacturer and take over a decade. These soaring costs are mostly a result of money invested in the 90% of candidate therapies that fail to enter the late stages of drug development, i.e., between phase 1 trials and regulatory approval. AI is projected to be the foundation for rapid, cheap, and efficient drug discovery and development. The integration of AI technology in cancer care could improve the accuracy and speed of diagnosis, aid in improved clinical decision-making, and lead to better health outcomes. AI-guided clinical care can play an important role in reducing health disparities, particularly in low-resource settings. Notably, the application areas of AI are expanding to include new approaches for cancer detection, screening, diagnosis and classification; cancer genomics characterization; tumor microenvironment analysis; and predictive and prognostic biomarkers assessment. AI can enhance many processes that are directly and indirectly related to the drug discovery and development. It can be used for improved tumor classification, computer-aided organic synthesis, compound discovery, assay development, and biomarker and target discovery. In general, AI aims to automate and optimize slow processes to substantially speed up the R&D drug discovery process. Several pharmaceutical, biotech, and software companies are making efforts to integrate AI into drug discovery and development. In 2016, Pfizer partnered with IBM Watson Health, an AI platform provider, to enhance its search for immuno-oncology treatments. Sanofi joined forces with Exscientia, the spin-out of Dundee University, to discover metabolic-disease therapies. Thus, the increased use of AI in drug development and delivery would create significant opportunities for the growth of the metastatic cancer drug market during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metastatic cancer drugs market growth in the coming years. The market is expected to grow at a good CAGR during the forecast period.
Asia Pacific Metastatic Cancer Drugs Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Metastatic Cancer Drugs Market Segmentation
The market for Asia Pacific metastatic cancer drugs market is segmented into cancer type ,route of administration ,drug class , product , and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, haematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is bifurcated into intravenous and intramuscular. Based on drug class, the Asia Pacific metastatic cancer drugs market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics, and biosimilars. Based on end user, the market is segmented into hospital, specialty clinic, and others. By country, the Asia Pacific metastatic cancer drugs market is segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific.
Asia Pacific Metastatic Cancer Drugs Market – Companies Mentioned
AbbVie Inc. ; Amgen Inc. ; Bristol-Myers Squibb Company ; F. HOFFMANN-LA ROCHE LTD.; Novartis AG ; Astrazeneca ;Eli Lilly and Company; MERCK KGaA ; Pfizer Inc. (Arena Pharmaceutical GmbH) ; and Johnson and Johnson Services, Inc. are among the leading companies in the Asia Pacific metastatic cancer drugs market .
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Metastatic Cancer Drugs Market – By Cancer Type
1.3.2 Asia Pacific Metastatic Cancer Drugs Market – By Route of Administration
1.3.3 Asia Pacific Metastatic Cancer Drugs Market – By Drug Class
1.3.4 Asia Pacific Metastatic Cancer Drugs Market – By Product
1.3.5 Asia Pacific Metastatic Cancer Drugs Market – By End User
1.3.6 Asia Pacific Metastatic Cancer Drugs Market – By Country
2. Asia Pacific Metastatic Cancer Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Metastatic Cancer Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific– PEST Analysis
4.3 Expert Opinion
5. Asia Pacific Metastatic Cancer Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Metastatic Cancer
5.1.2 Government Initiatives to Support Developments in Cancer Treatment
5.2 Market Restraints
5.2.1 High Cost of Oncology Drugs
5.3 Market Opportunities
5.3.1 Investments in Artificial Intelligence for Oncology Drug Development
5.4 Future Trends
5.4.1 Increase in Launch of Metastatic Cancer Drugs
5.5 Impact analysis
6. Asia Pacific Metastatic Cancer Drugs Market – APAC Analysis
6.1 Asia Pacific Metastatic Cancer Drugs Market Revenue Forecast and Analysis
6.1.1 Asia Pacific Metastatic Cancer Drugs Market,- Forecast and Analysis
7. Asia Pacific Metastatic Cancer Drug Market Analysis – By Cancer Type
7.1 Overview
7.2 Asia Pacific Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)
7.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)
7.3 Breast Cancer
7.3.1 Overview
7.3.2 Breast Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Lung Cancer
7.4.1 Overview
7.4.2 Lung Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Liver Cancer
7.5.1 Overview
7.5.2 Liver Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Hematological Cancer
7.6.1 Overview
7.6.2 Hematological Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Brain Cancer
7.7.1 Overview
7.7.2 Brain Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Prostate Cancer
7.8.1 Overview
7.8.2 Prostate Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pancreatic Cancer
7.9.1 Overview
7.9.2 Pancreatic Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8. Asia Pacific Metastatic Cancer Drug Market – By Route of Administration
8.1 Overview
8.2 Asia Pacific Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)
8.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)
8.3 Intravenous
8.3.1 Overview
8.3.2 Intravenous: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Intramuscular
8.4.1 Overview
8.4.2 Intramuscular: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Oral
8.5.1 Overview
8.5.2 Oral: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9. Asia Pacific Metastatic Cancer Drug Market – By Drug Class
9.1 Overview
9.2 Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)
9.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)
9.3 HER2 Inhibitors
9.3.1 Overview
9.3.2 HER2 Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Immune Checkpoints Inhibitors
9.4.1 Overview
9.4.2 Immune Checkpoints Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.5 PARP Inhibitors
9.5.1 Overview
9.5.2 PARP Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Kinase Inhibitors
9.6.1 Overview
9.6.2 Kinase Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
10. Asia Pacific Metastatic Cancer Drug Market – By Product
10.1 Overview
10.2 Asia Pacific Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)
10.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)
10.3 Branded
10.3.1 Overview
10.3.2 Branded: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Generics and Biosimilars
10.4.1 Overview
10.4.2 Generics and Biosimilars: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11. Asia Pacific Metastatic Cancer Drug Market – By End User
11.1 Overview
11.2 Asia Pacific Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)
11.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)
11.3 Hospital
11.3.1 Overview
11.3.2 Hospitals: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11.4 Specialty Clinic
11.4.1 Overview
11.4.2 Specialty Clinics: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
12. Asia Pacific Metastatic Cancer Drugs Market – Regional Analysis
12.1 Asia Pacific: Asia Pacific Metastatic Cancer Drugs Market
12.1.1 Overview
12.1.2 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)
12.1.2.1 China: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.1.1 China: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.1.2 China: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)
12.1.2.1.3 China: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)
12.1.2.1.4 China: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)
12.1.2.1.5 China: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)
12.1.2.1.6 China: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)
12.1.2.2 Japan: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.2.1 Japan: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.2.2 Japan: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)
12.1.2.2.3 Japan: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)
12.1.2.2.4 Japan: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)
12.1.2.2.5 Japan: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)
12.1.2.2.6 Japan: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)
12.1.2.3 India: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.3.1 India: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.3.2 India: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)
12.1.2.3.3 India: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)
12.1.2.3.4 India: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)
12.1.2.3.5 India: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)
12.1.2.3.6 India: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)
12.1.2.4 Australia: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.4.1 Australia: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.4.2 Australia: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)
12.1.2.4.3 Australia: Asia Pacific Metastatic Cancer Drug Market, By Route of Administrations, 2019–2028 (USD Million)
12.1.2.4.4 Australia: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)
12.1.2.4.5 Australia: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)
12.1.2.4.6 Australia: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)
12.1.2.5 South Korea: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.5.1 South Korea: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.5.2 South Korea: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)
12.1.2.5.3 South Korea: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)
12.1.2.5.4 South Korea: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)
12.1.2.5.5 South Korea: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)
12.1.2.5.6 South Korea: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)
12.1.2.6 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.6.1 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
12.1.2.6.2 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)
12.1.2.6.3 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)
12.1.2.6.4 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)
12.1.2.6.5 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)
12.1.2.6.6 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)
13. Asia Pacific Metastatic Cancer Drug Market –Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market, 2021-2028
13.3 Inorganic Developments
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 AbbVie Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Amgen Inc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Bristol-Myers Squibb Company
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 F. HOFFMANN-LA ROCHE LTD.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Novartis AG
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Astrazeneca
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Eli Lilly and Company.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 MERCK KGaA
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Johnson and Johnson Services, Inc.
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, – Revenue and Forecast to 2028 (USD Million)
Table 2. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 3. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 4. Asia Pacific Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)
Table 5. Asia Pacific Asia Pacific Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 6. Asia Pacific Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 7. China: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 8. China: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 9. China: Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)
Table 10. China: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 11. China: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 12. Japan: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)
Table 13. Japan: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration– Revenue and Forecast to 2028 (USD Million)
Table 14. Japan: Asia Pacific Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 15. Japan: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 16. Japan: Asia Pacific Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 17. India: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)
Table 18. India: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration– Revenue and Forecast to 2028 (USD Million)
Table 19. India: Asia Pacific Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 20. India: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 21. India: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 22. Australia: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 23. Australia: Asia Pacific Metastatic Cancer Drug Market, By Route of Administrations – Revenue and Forecast to 2028 (USD Million)
Table 24. Australia: Asia Pacific Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 25. Australia: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 26. Australia: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 27. South Korea: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 28. South Korea: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 29. South Korea: Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)
Table 30. South Korea: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 31. South Korea: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 32. Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 33. Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 34. Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)
Table 35. Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 36. Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 37. Recent Inorganic Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market
Table 38. Recent Organic Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market
Table 39. Glossary of Terms, Asia Pacific Metastatic Cancer Drugs Market
LIST OF FIGURES
Figure 1. Asia Pacific Metastatic Cancer Drugs Market Segmentation
Figure 2. Asia Pacific Metastatic Cancer Drugs Market Overview
Figure 3. The PARP Inhibitors Segment Held The Largest Share of Drug Class Segment in Asia Pacific Metastatic Cancer Drugs Market
Figure 4. China Is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Asia Pacific PEST Analysis
Figure 6. Expert Opinion
Figure 7. Asia Pacific Metastatic Cancer Drugs Market Impact Analysis of Driver and Restraints
Figure 8. Asia Pacific Metastatic Cancer Drugs Market – Revenue Forecast and Analysis – 2021- 2028
Figure 9. Asia Pacific Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)
Figure 10. Breast Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Lung Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Liver Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Hematological Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Brain Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Prostate Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Pancreatic Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Asia Pacific Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)
Figure 19. Intravenous: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Intramuscular: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Oral: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)
Figure 24. HER2 Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Immune Checkpoints Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. PARP Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Kinase Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Asia Pacific Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)
Figure 30. Branded: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Generics and Biosimilars: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Asia Pacific Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)
Figure 33. Hospitals: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Specialty Clinics: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Key Country – Revenue (2021) (USD Million)
Figure 37. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)
Figure 38. China: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Japan: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
Figure 40. India: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
Figure 41. Australia: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
Figure 42. South Korea: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
Figure 43. Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)
Figure 44. Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market, 2021-2028
- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- Novartis AG
- Astrazeneca
- Eli Lilly and Company
- MERCK KGaA
- Pfizer Inc. (Arena Pharmaceutical GmbH)
- Johnson and Johnson Services, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Metastatic Cancer Drugs Market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Metastatic Cancer Drugs Market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.